Mammalian

AtaGenix's mammalian protein expression platform offers both transient and stable production routes using CHO and HEK293 host cells. Mammalian expression ensures native post-translational modifications — including complex N-linked glycosylation, disulfide bond formation, and proper folding — critical for therapeutic antibodies, Fc-fusion proteins, and receptor ectodomains.

Choose transient expression for rapid milligram-scale delivery (as fast as 2 weeks), ideal for early screening, SPR binding studies, and animal studies. Choose stable cell line development when you need consistent, long-term gram-scale supply for preclinical and manufacturing use — our clonally-derived CHO lines achieve titers exceeding 7 g/L in fed-batch.

Our proprietary XtenCHO™ high-density expression system is specifically optimized for difficult-to-express proteins, delivering higher titers and faster development timelines compared to standard CHO platforms. All projects are managed by PhD-level scientists with full QC documentation and IP ownership transfer.